GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management.
It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019.
GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
A real-time developer of saliva-based tests for SARS-CoV-2.
- Sector(s): Healthcare
- Industry: Medical Devices
- Full Time Employees: 7
- Founded in 2016
- Headquartered in New York,
- http://www.gbs.inc
Priced its IPO of 1,270,589 units at $17.00/unit.
No comments:
Post a Comment